Cantor Fitzgerald Reiterates Overweight on Celldex Therapeutics, Maintains $67 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Kristen Kluska has reiterated an Overweight rating on Celldex Therapeutics (NASDAQ:CLDX) and maintained a price target of $67.
September 16, 2024 | 3:35 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Celldex Therapeutics, maintaining a $67 price target, indicating confidence in the company's potential.
The reiteration of an Overweight rating and maintenance of a $67 price target by Cantor Fitzgerald suggests a positive outlook for Celldex Therapeutics. This could lead to increased investor confidence and potential upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100